Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Go back to Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting| (NASDAQ: STRO) | Delayed: 18.36 -0.74 (3.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.10 | 52 Week High | $ | |||
| Open | $19.01 | 52 Week Low | $ | |||
| Day High | $19.46 | P/E | N/A | |||
| Day Low | $18.24 | EPS | $ | |||
| Volume | 145,606 | |||||
